case_images: PMC10460171_01
case_images: Psoriasis worsened (trunk).
case_images: PTT-13-27-g0001.jpg
case_images: PMC10460171_01_PTT-13-27-g0001.jpg
case_images: f0001
case_images: While BP improved rapidly with BPDAI 16, psoriasis worsened (Figures 1 and Figure 2).
case_images: Psoriasis worsened (lower limbs).
case_images: PTT-13-27-g0002.jpg
case_images: PMC10460171_01_PTT-13-27-g0002.jpg
case_images: f0002
case_images: While BP improved rapidly with BPDAI 16, psoriasis worsened (Figures 1 and Figure 2).
case_images: Clinical remission of both psoriatic e PB lesions on the trunk after DMF therapy.
case_images: PTT-13-27-g0003.jpg
case_images: PMC10460171_01_PTT-13-27-g0003.jpg
case_images: f0003
case_images: At his most recent follow-up visit, 12 months after the initiation of risankizumab therapy, no relapse of both diseases was seen (Figures 3 and Figure 4).    
case_images: Clinical remission on lower limbs.
case_images: PTT-13-27-g0004.jpg
case_images: PMC10460171_01_PTT-13-27-g0004.jpg
case_images: f0004
case_images: At his most recent follow-up visit, 12 months after the initiation of risankizumab therapy, no relapse of both diseases was seen (Figures 3 and Figure 4).    